Mylan Specialty Grants & Donations Portal

Mylan Specialty is committed to supporting educational initiatives that facilitate health care provider education, advance the quality of patient care, and align with Mylan Specialty's therapeutic and clinical interests. We also partner with charitable organizations that meet these criteria.

 Through our online application system, you and/or your organization can apply for the following:

  • CME or Non-CME Grants
  • EpiPen® (epinephrine) Auto-Injector Product Donations
  • Monetary Donation

If you would like to submit a request for an Investigator Initiated Trial (IIT) please click here.

Mylan Specialty L.P. will be accepting applications starting Tuesday, January 16, 2018 through Friday, April 27, 2018. The portal will re-open, Monday, July 2, 2018 through Friday, September 28, 2018. Mylan Specialty L.P. will be accepting educational initiatives for activities in the areas of interest listed below.

2018 Unrestricted Educational Grants Priority Topics

Asthma/COPD, Biosimilars, and HIV/ARV

Asthma and COPD

  • Generics in Respiratory
  • Combination treatment strategy in COPD, specifically LABA/LAMA
  • Triple Combination Therapy in COPD
  • Role of ICS/LABA in COPD
  • Nebulization therapy in COPD
  • Nebulization in Acute Care Settings
  • Identification of at risk populations who might benefit from nebulized therapy
  • Cost effectiveness of nebulized therapy
  • Ability to improve adherence compliance with nebulized therapy
  • Current and evolving COPD treatment strategy for discharge after acute exacerbations, the re-hospitalization, prevention and 30-day readmission
  • New devices/delivery systems
  • Asthma-COPD overlap syndrome (ACOS)
  • COPD: Special population (older, cognitively impaired, ethnic groups, dexterity, other)
  • Annual Respiratory conferences: scientific programs and educational symposia

Biosimilars

  • Use of Biosimilars in Oncology
  • Use of Biosimilars in Diabetes
  • Use of Biosimilars in chemo-induced neutropenia
  • Regulatory pathway for FDA approval of Biosimilars

HIV/ARV

  • Role of Novel ARV Guidelines/ Substitutable therapies
  • FDCs with reduced doses in HIV treatment
  • Role of new once daily combinations based on older compounds
  • Current and evolving HIV treatment strategy
  • Annual HIV conferences: scientific programs